SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
1-Year Return
0.41%
This Quarter Return
+10.94%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$382M
AUM Growth
-$23M
(-5.7%)
Cap. Flow
-$40.1M
Cap. Flow
% of AUM
-10.48%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
131
New
16
Increased
23
Reduced
53
Closed
27
Top Buys
| 1 |
Tower Semiconductor
TSEM
|
$8.81M |
| 2 |
Biogen
BIIB
|
$7.54M |
| 3 |
Forte Biosciences
FBRX
|
$6.4M |
| 4 |
Cytokinetics
CYTK
|
$6.01M |
| 5 |
Cidara Therapeutics
CDTX
|
$5.89M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$12.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$6.08M |
| 3 |
Nice
NICE
|
$5.13M |
| 4 |
Merus
MRUS
|
$4.48M |
| 5 |
Sanofi
SNY
|
$4.11M |
Sector Composition
| 1 | Healthcare | 73.22% |
| 2 | Technology | 19.05% |
| 3 | Consumer Discretionary | 1.86% |
| 4 | Utilities | 1.71% |
| 5 | Communication Services | 1.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
CEVA Inc
CEVA
$527M
| $1.08M | 0.25% |
48,920
| – | – |
|
77
Perspective Therapeutics
CATX
$250M
| $1.07M | 0.25% |
310,343
-149,904
| -33% | -$516K |
|
78
Cogent Biosciences
COGT
$1.79B
| $1.03M | 0.24% |
143,693
-191,331
| -57% | -$1.37M |
|
79
Krystal Biotech
KRYS
$4.29B
| $1.01M | 0.24% |
+7,335
| New | +$1.01M |
|
80
Taysha Gene Therapies
TSHA
$870M
| $970K | 0.23% |
+420,000
| New | +$970K |
|
81
ProMIS Neurosciences
PMN
$22.6M
| $919K | 0.22% |
1,899,297
-30,000
| -2% | -$14.5K |
|
82
VistaGen Therapeutics
VTGN
$114M
| $896K | 0.21% |
447,939
-342,611
| -43% | -$685K |
|
|
CMMB
83
Chemomab Therapeutics
CMMB
$15.9M
| $856K | 0.2% |
184,512
-40,595
| -18% | -$188K |
|
84
Bristol-Myers Squibb
BMY
$94.5B
| $810K | 0.19% |
17,500
-2,500
| -13% | -$116K |
|
85
Corvus Pharmaceuticals
CRVS
$419M
| $732K | 0.17% |
183,094
-22,765
| -11% | -$91.1K |
|
86
Werewolf Therapeutics
HOWL
$61.3M
| $683K | 0.16% |
626,810
| – | – |
|
87
Verastem
VSTM
$623M
| $678K | 0.16% |
+163,307
| New | +$678K |
|
|
BCAX
88
Bicara Therapeutics Inc. Common Stock
BCAX
$642M
| $610K | 0.14% |
+65,679
| New | +$610K |
|
89
Larimar Therapeutics
LRMR
$325M
| $568K | 0.13% |
196,635
-169,669
| -46% | -$490K |
|
90
SentinelOne
S
$5.95B
| $494K | 0.12% |
+27,000
| New | +$494K |
|
91
Aprea Therapeutics
APRE
$8.68M
| $456K | 0.11% |
270,000
| – | – |
|
92
Cognyte Software
CGNT
$631M
| $417K | 0.1% |
+45,181
| New | +$417K |
|
93
Kezar Life Sciences
KZR
$28.4M
| $268K | 0.06% |
58,539
-49,934
| -46% | -$229K |
|
|
CLYM
94
Climb Bio, Inc. Common Stock
CLYM
$155M
| $260K | 0.06% |
209,837
-32,098
| -13% | -$39.8K |
|
95
Solid Biosciences
SLDB
$424M
| $244K | 0.06% |
+50,190
| New | +$244K |
|
96
PepGen
PEPG
$42M
| $174K | 0.04% |
+156,467
| New | +$174K |
|
|
OKUR
97
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$36.5M
| $144K | 0.03% |
60,454
-20,000
| -25% | -$47.8K |
|
|
ELEV
98
DELISTED
Elevation Oncology
ELEV
| $121K | 0.03% |
328,562
-30,000
| -8% | -$11K |
|
99
Jasper Therapeutics
JSPR
$42.1M
| $81.4K | 0.02% |
14,671
-107,346
| -88% | -$596K |
|
100
Applied Therapeutics
APLT
$68.7M
| $15.6K | ﹤0.01% |
50,000
| – | – |
|